Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study
Background: Left ventricular assist device (LVAD) implantation provides a robust survival advantage, however despite improvements in mortality, the adverse event burden of durable mechanical circulatory support remains high. Bleeding complications are one such significant complication. The uSTOP LVA...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | American Heart Journal Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602222000593 |
| _version_ | 1817976417049116672 |
|---|---|
| author | Mustafa M. Ahmed Lauren E. Meece Eileen M. Handberg Carl J. Pepine |
| author_facet | Mustafa M. Ahmed Lauren E. Meece Eileen M. Handberg Carl J. Pepine |
| author_sort | Mustafa M. Ahmed |
| collection | DOAJ |
| description | Background: Left ventricular assist device (LVAD) implantation provides a robust survival advantage, however despite improvements in mortality, the adverse event burden of durable mechanical circulatory support remains high. Bleeding complications are one such significant complication. The uSTOP LVAD BLEED (Utilization of umbilical cord lining Stem cells TO Prevent LVAD associated angiodysplastic BLEEDing) pilot study is designed to evaluate the safety and tolerability of escalating doses of umbilical cord lining stem cells (ULSCs) in LVAD recipients to ameliorate the dysregulation of angiogenic factors seen in this population. Design: This Phase Ia single-ascending dose pilot study will evaluate the IV administration of ULSCs in stable out-patients supported with an LVAD. In a 3 + 3 design, a maximum of 18 patients will receive an IV infusion of ULSCs. Main outcome measures: The primary endpoints are safety and tolerability, secondary exploratory endpoints will include biomarker evaluation of angiogenic dysregulation. Summary: This represents a novel cell type and route of administration in this population, while collecting initial data regarding the magnitude and duration of effects of cell therapy, and assessing the possibility of decreasing bleeding by a strategy of vascular stabilization. Clinical trial registration: ClinicalTrials.gov Identifier: NCT04811261. https://clinicaltrials.gov/ct2/show/NCT04811261. |
| first_indexed | 2024-04-13T22:02:19Z |
| format | Article |
| id | doaj.art-aae8b19f135f41659ae770da7d29ea5e |
| institution | Directory Open Access Journal |
| issn | 2666-6022 |
| language | English |
| last_indexed | 2024-04-13T22:02:19Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Heart Journal Plus |
| spelling | doaj.art-aae8b19f135f41659ae770da7d29ea5e2022-12-22T02:28:03ZengElsevierAmerican Heart Journal Plus2666-60222022-04-0116100142Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot studyMustafa M. Ahmed0Lauren E. Meece1Eileen M. Handberg2Carl J. Pepine3Corresponding author at: 1329 SW 16th St., Gainesville, FL 32610, United States of America.; University of Florida, Division of Cardiovascular Medicine, Gainesville, FL, United States of AmericaUniversity of Florida, Division of Cardiovascular Medicine, Gainesville, FL, United States of AmericaUniversity of Florida, Division of Cardiovascular Medicine, Gainesville, FL, United States of AmericaUniversity of Florida, Division of Cardiovascular Medicine, Gainesville, FL, United States of AmericaBackground: Left ventricular assist device (LVAD) implantation provides a robust survival advantage, however despite improvements in mortality, the adverse event burden of durable mechanical circulatory support remains high. Bleeding complications are one such significant complication. The uSTOP LVAD BLEED (Utilization of umbilical cord lining Stem cells TO Prevent LVAD associated angiodysplastic BLEEDing) pilot study is designed to evaluate the safety and tolerability of escalating doses of umbilical cord lining stem cells (ULSCs) in LVAD recipients to ameliorate the dysregulation of angiogenic factors seen in this population. Design: This Phase Ia single-ascending dose pilot study will evaluate the IV administration of ULSCs in stable out-patients supported with an LVAD. In a 3 + 3 design, a maximum of 18 patients will receive an IV infusion of ULSCs. Main outcome measures: The primary endpoints are safety and tolerability, secondary exploratory endpoints will include biomarker evaluation of angiogenic dysregulation. Summary: This represents a novel cell type and route of administration in this population, while collecting initial data regarding the magnitude and duration of effects of cell therapy, and assessing the possibility of decreasing bleeding by a strategy of vascular stabilization. Clinical trial registration: ClinicalTrials.gov Identifier: NCT04811261. https://clinicaltrials.gov/ct2/show/NCT04811261.http://www.sciencedirect.com/science/article/pii/S2666602222000593Left ventricular assist deviceLVADBleeding |
| spellingShingle | Mustafa M. Ahmed Lauren E. Meece Eileen M. Handberg Carl J. Pepine Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study American Heart Journal Plus Left ventricular assist device LVAD Bleeding |
| title | Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study |
| title_full | Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study |
| title_fullStr | Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study |
| title_full_unstemmed | Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study |
| title_short | Intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint: Rational and design of the uSTOP LVAD BLEED pilot study |
| title_sort | intravenous administration of umbilical cord lining stem cells in left ventricular assist device recpieint rational and design of the ustop lvad bleed pilot study |
| topic | Left ventricular assist device LVAD Bleeding |
| url | http://www.sciencedirect.com/science/article/pii/S2666602222000593 |
| work_keys_str_mv | AT mustafamahmed intravenousadministrationofumbilicalcordliningstemcellsinleftventricularassistdevicerecpieintrationalanddesignoftheustoplvadbleedpilotstudy AT laurenemeece intravenousadministrationofumbilicalcordliningstemcellsinleftventricularassistdevicerecpieintrationalanddesignoftheustoplvadbleedpilotstudy AT eileenmhandberg intravenousadministrationofumbilicalcordliningstemcellsinleftventricularassistdevicerecpieintrationalanddesignoftheustoplvadbleedpilotstudy AT carljpepine intravenousadministrationofumbilicalcordliningstemcellsinleftventricularassistdevicerecpieintrationalanddesignoftheustoplvadbleedpilotstudy |